Summary:
Click image to enlarge
A 52-week, multicenter, randomized, double-blind study of secukinumab (300mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriais (CLARITY).
Qualified Participants Must:
• Be 18 years of age or older
•
Have a diagnosis of moderate to severe plaque psoriasis
Qualified Participants May Receive:
- Study medication at no cost
- Compensation for time and travel